scholarly journals Recent development in the artificial treatment for dry eye disease

2020 ◽  
Vol 11 (3) ◽  
pp. 2848-2857 ◽  
Author(s):  
Priyavarshini R ◽  
Amit B Patil
Keyword(s):  
Environmental Changes ◽  
Tear Film ◽  
Meibomian Gland ◽  
Eye Disease ◽  
Eye Drops ◽  
Omega 3 Fatty Acids ◽  
Omega 3 ◽  
Artificial Tears ◽  
Dry Eyes ◽  
The Common

Eyes are the most important organs of the human body. The important parts of the eyes are conjunctiva, cornea, Iris, pupil, retina, sclera. Eye is protected by eyelid from external environment. The common eye disease is kerato conjunctivitis sicca (KCS) i.e dry eyes syndrome. Tear is secreted by a lacrimal gland which lubricates the eye. The dry eyes disease syndrome commonly is caused because tears are not secreted properly by the tear duct or the tear film gets evaporated from the surface of the eye due to various factors or due to environmental changes. Dry eyes disease caused due to age, environmental factor like increase in air pollution, increase in temperature, humidity in the atmosphere, using contact lens, medication also causes dry eyes. This article reviews the causes, symptoms, and recent treatment system of dry eyes disease. Dry eyes can be treated by using medications like artificial tears, Carmellose artificial tears eye drops, Cyclosporine A, Difluprednate, Lacrisert nutritional supplements, omega-3 fatty acids, etc. The therapy like Meibomian gland expression, Intense pulsed light, Lipiflow, etc. the dry eyes disease not only affecting human eye but it also affects animals like dogs and cat.

scholarly journals Meibomian Gland Dysfunction

2019 ◽  
Vol 35 (1) ◽  
Author(s):  
Sameera Irfan
Keyword(s):  
Dry Eye ◽  
Ocular Surface ◽  
Treatment Strategies ◽  
Tear Film ◽  
Meibomian Gland ◽  
Dry Eye Disease ◽  
Meibomian Gland Dysfunction ◽  
Eye Disease ◽  
Treatment Protocols ◽  
Dry Eyes

Dry eyes is a common, chronic condition that has a prevalence of about 5- 50%.1 According to the Dry Eye Workshop II report (DEWS II report), published in 2017, the updated definition of Dry Eye Disease is, “a multifactorial disease of the ocular surface characterised by a loss of homeostasis of the tear film, and accompanied by ocular symptoms, in which tear film instability and hyper-osmolarity, ocular surface inflammation and damage, and neurosensory abnormalities play etiological roles.” The Tear Film & Ocular Surface Society (TFOS) released their report on the international work on Meibomian Gland Dysfunction (MGD)2 in 2011, which defined MGD, classified it and considered it as the primary cause of dry eye disease worldwide. Previously dry eye disease was considered as an aqueous deficiency problem, but after this report by TFOS, there is a paradigm shift towards “not producing enough lipids to retain the tears that are being produced”. This has led to a huge impact on the treatment protocols which were previously focused on managing the sequelae and symptoms of dry eyes rather than targeting directly on the underlying cause, the MGD. It has now been accepted worldwide that dry eye occurs when the ocular surface system cannot adequately protect itself from the desiccating stress due to the lack of a healthy meibomian gland secretion. This article is mainly focussed on the Meibomian Gland Dysfunction, discussing the normal anatomy of the glands, how they are affected by disease, its implications on the ocular surface and finally, the various treatment strategies. Key words: Blepharitis, Dry eyes, Meibomian gland dysfunction, blepharospasm.

scholarly journals The HYLAN M Study: Efficacy of 0.15% High Molecular Weight Hyaluronan Fluid in the Treatment of Severe Dry Eye Disease in a Multicenter Randomized Trial

2020 ◽  
Vol 9 (11) ◽  
pp. 3536 ◽  
Author(s):  
Gysbert-Botho van Setten ◽  
Christophe Baudouin ◽  
Jutta Horwath-Winter ◽  
Daniel Böhringer ◽  
Oliver Stachs ◽  
...  
Keyword(s):  
Molecular Weight ◽  
High Molecular Weight ◽  
Dry Eye ◽  
Tear Film ◽  
Dry Eye Disease ◽  
Eye Disease ◽  
Control Group ◽  
Eye Drops ◽  
Artificial Tears ◽  
Ocular Surface Disease Index

The aim of the HYLAN M study was to investigate if symptoms and/or signs of patients suffering from severe dry eye disease (DED) can be improved by substituting individually optimized artificial tear therapy by high molecular weight hyaluronan (HMWHA) eye drops. In this international, multicenter study, patients with symptoms of at least ocular surface disease index (OSDI) 33 and corneal fluorescein staining (CFS) of at least Oxford grade 3 were included. A total of 84 per-protocol patients were randomized in two study arms. The control group continued to use their individual optimum artificial tears over the study period of eight weeks; in the verum group, the artificial tears were substituted by eye drops containing 0.15% HMWHA. At the week 8 visit, the average OSDI of the verum group had improved by 13.5 as compared to the control group (p = 0.001). The best corrected visual acuity (BCVA) had improved by 0.04 logMAR (p = 0.033). CFS, tear film break-up time (TBUT), Schirmer I, lid wiper epitheliopathy (LWE), mucocutaneous junction (Yamaguchi score), and tear osmolarity were not significantly different between the verum and control groups (p > 0.050). We conclude that for most patients with severe DED, 0.15% HMWHA eye drops provide excellent improvement of symptoms without impairment of dry eye signs.

scholarly journals A STUDY ON PREVALENCE OF DRY EYES IN A TERTIARY PRIVATE HOSPITAL

2019 ◽  
Vol 3 (9) ◽  
Author(s):  
Dr. Rajani .
Keyword(s):  
Dry Eye ◽  
Tear Film ◽  
Visual Disturbance ◽  
Meibomian Gland ◽  
Dry Eye Disease ◽  
Eye Disease ◽  
Age Group ◽  
Dry Eyes ◽  
Ocular Irritation ◽  
Breakup Time

Introduction: Dry eye disease (DED) is a multifactorial ocular surface disease characterized by symptoms of discomfort, irritation, and visual disturbance. Dry eye disease (DED), either alone or in combination with other conditions, is a frequent cause of ocular irritation that leads the patients to seek ophthalmic care Materials & Methods: 150 study subjects were enrolled for the study. A cross-section hospital-based, observational study was conducted. Results: Among the study subjects the maximum were from 61-70 year age group, followed by 51-60 year age group. Prevalence of DED was detected in 30%. Keywords: Dry eye, Kadapa, Meibomian gland dysfunction, Tear film breakup time

scholarly journals Cationic Thiolated Poly(aspartamide) Polymer as a Potential Excipient for Artificial Tear Formulations

2016 ◽  
Vol 2016 ◽  
pp. 1-8 ◽  
Author(s):  
Mária Budai-Szűcs ◽  
Gabriella Horvát ◽  
Barnabás Áron Szilágyi ◽  
Benjámin Gyarmati ◽  
András Szilágyi ◽  
...  
Keyword(s):  
Dry Eye ◽  
Tear Film ◽  
Dry Eye Disease ◽  
Eye Disease ◽  
Eye Drops ◽  
Thiol Groups ◽  
Physiological Properties ◽  
Disulphide Bond Formation ◽  
Polymer Bearing

Dry eye disease is a relatively common ocular problem, which causes eye discomfort and visual disorders leading to a decrease in the quality of life. The aim of this study was to find a possible excipient for eye drop formulations, which is able to stabilize the tear film. A cationic thiolated polyaspartamide polymer, poly[(N-mercaptoethylaspartamide)-co-(N-(N′,N′-dimethylaminoethyl)aspartamide)] (ThioPASP-DME), was used as a potential vehicle. Besides satisfying the basic requirements, the chemical structure of ThioPASP-DME is similar to those of ocular mucins as it is a protein-like polymer bearing a considerable number of thiol groups. The solution of the polymer is therefore able to mimic the physiological properties of the mucins and it can interact with the mucus layer via disulphide bond formation. The resultant mucoadhesion provides a prolonged residence time and ensures protective effect for the corneal/conjunctival epithelium. ThioPASP-DME also has an antioxidant effect due to the presence of the thiol groups. The applicability of ThioPASP-DME as a potential excipient in eye drops was determined by means of ocular compatibility tests and through examinations of the interactions with the mucosal surface. The results indicate that ThioPASP-DME can serve as a potential eye drop excipient for the therapy of dry eye disease.

scholarly journals Determination of Risk Factors and Treatment of Dry Eye Disease in Type 1 Diabetes Before Corneal Complications at Sindh Institute of Ophthalmology And Visual Sciences

2017 ◽  
Vol 11 (1) ◽  
pp. 355-361 ◽  
Author(s):  
Shehnilla Shujaat ◽  
Muhammad Jawed ◽  
Shahzad Memon ◽  
Khalid Iqbal Talpur
Keyword(s):  
Risk Factors ◽  
Type 1 Diabetes ◽  
Dry Eye ◽  
Tear Film ◽  
Dry Eye Disease ◽  
Eye Disease ◽  
Diabetic Patients ◽  
Dry Eyes ◽  
Department Of Ophthalmology

Objective: The objective of this study was to assess and determine the risk factors and treatment of dry eye disease in type 1 diabetes before any ocular surface or corneal complication occurs. This study was conducted at Sindh Institute of Ophthalmology And Visual Sciences, Hyderabad, Pakistan. Methodology: Subjects and methods for observational study were undertaken at the Department of Ophthalmology Sindh Institute Of Ophthalmology And Visual Sciences, Hyderabad, Pakistan. Hundred confirmed cases of type 1 diabetes were included in the study by non probability convenience sampling. Tear film breakup time and schrimer test were carried out to determine dry eye disease. Data was collected by self-prepared questionnaire and entered and analyzed by using Statistical Program for Social Sciences (SPSS, version 20.0). The frequencies and percentage were recorded and any associations with predisposing factors were statistically analyzed by t test. Results: Out of hundred patients, 71 (71%) were found to have dry eyes (P<0.001). The mean age of the subject in this study was 50.97 years (range 30-70 years). Old age was related to high risk of dry eye disease (P<0.001). There was no big difference in the incidence of dry eyes in males and females. Long duration was found to be related with increased occurrence of dry eyes (P<0.001). We found higher values for abnormal tear film break up time than schirmer test values leading to increased occurrence of evaporative dry eyes. Conclusion: There is marked increase in frequency/ risk of developing dry eye disease in type 1 diabetes patients. Therefore, it is recommended to have periodic ophthalmic examination for type 1 diabetic patients.

scholarly journals Deciphering the Action of Perfluorohexyloctane Eye Drops to Reduce Ocular Discomfort and Pain

2021 ◽  
Vol 8 ◽  
Author(s):  
Miguel Delicado-Miralles ◽  
Enrique Velasco ◽  
Ariadna Díaz-Tahoces ◽  
Juana Gallar ◽  
M. Carmen Acosta ◽  
...  
Keyword(s):  
Surface Temperature ◽  
Dry Eye ◽  
Meibomian Gland ◽  
Dry Eye Disease ◽  
Eye Disease ◽  
Eye Drops ◽  
Phenol Red ◽  
Corneal Surface ◽  
Healthy Humans ◽  
Ocular Discomfort

Perfluorohexyloctane (F6H8) eyedrops have been recently introduced in Europe as a product to treat dry eye disease, based on its ability to reduce tear film instability in Meibomian gland dysfunction and evaporative dry eye disease, although its mechanism of action is still unknown. In the present pilot study, we evaluated the effects of the ocular instillation of a single drop of commercial F6H8 eyedrops in 20 healthy humans (9 women/11 men), measuring: (a) Corneal surface temperature (CST) from infrared video images; (b) tear volume using phenol red threads; (c) blinking frequency; and (d) ocular surface sensations (cold, dryness, pricking, foreign body, burning, itching, gritty, eye fatigue, watering eyes, and light-evoked discomfort sensations; scored using 10 cm Visual Analog Scales), before and 5–60 min after F6H8 or saline treatment. CST decreased and tearing and blinking frequency increased significantly after F6H8 but not after saline solution. When applied unilaterally, CST decreased only in the F6H8-treated eye. No sensations were evoked after F6H8 or saline. The corneal surface temperature reduction produced by topical F6H8 does not evoke conscious ocular sensations but is sufficient to increase the activity of corneal cold thermoreceptors, leading to an increased reflex lacrimation and blinking that may relieve dry eye condition thus reducing ocular discomfort and pain.

scholarly journals Efficacy of hyaluronic acid 0.3%, cyanocobalamin, electrolytes, and P-Plus in menopause patients with moderate dry eye disease

2021 ◽  
Author(s):  
Concepción De-Hita-Cantalejo ◽  
María Carmen Sánchez-González ◽  
Carmen Silva-Viguera ◽  
Marta C. García-Romera ◽  
Ricardo Feria-Mantero ◽  
...  
Keyword(s):  
Hyaluronic Acid ◽  
Vitamin B12 ◽  
Dry Eye ◽  
Meibomian Gland ◽  
Dry Eye Disease ◽  
Eye Disease ◽  
Eye Drops ◽  
Phenol Red ◽  
Prospective Longitudinal Study ◽  
Prospective Longitudinal

Abstract Purpose To study the treatment efficacy of hyaluronic acid 0.3%, cyanocobalamin (vitamin B12), electrolytes, and P-Plus in menopausal patients with moderate dry eye disease. Methods Thirty female patients of mean age 53.06 ± 5.20 years (45–65) were enrolled in this prospective longitudinal study. Meibomian gland loss assessment was determined using a scale with four levels. The Ocular Surface Disease Index (OSDI) questionnaire, phenol red thread (PRT) test, and tear film break-up time (TFBUT) were also completed by the patients. Tear eye drops were formulated with 0.3 g of sodium hyaluronate, P-Plus ™, vitamin B12, sodium chloride, potassium chloride, calcium chloride, magnesium chloride, and SCO® (stabilized complex oxychloride). After 30 days, the patients were re-evaluated. Results The mean meibomian gland loss percentage was 37.97 ± 19.02 % (7.20 to 88.30%). Before treatment, the OSDI was 22.53 ± 14.03 score points (6.25 to 77.08). Posterior OSDI decreased to 16.26 ± 13.69 score points (0.00 to 70.83) (W = 58.00, P < 0.01). Before treatment, PRT was 10.31 ± 4.48 mm (4.00 to 21.00). Posterior PRT increased to 15.41 ± 6.27 mm (4.00 to 21.00) (W = 1520.50, P < 0.01). Before treatment, TFBUT was 6.23 ± 1.75 s (3.00 to 9.00). The posterior TFBUT increased to 8.10 ± 2.06 s (4.00 to 14.00) (W= 1382.50, P < 0.01). Conclusion The hyaluronic acid 0.3% and vitamin B12 eye drops effectively decreased dry eye symptoms in menopausal women and improved tear stability and volume.

Sign in / Sign up

Export Citation Format

Share Document